Inozyme Pharma, Inc. CEO and Chairman Doug Treco, Ph.D., will be participating in a fireside chat at the Bank of America Securities 2024 Health Care Conference on May 15th, 2024. The chat will take place from 6:40-7:10pm ET / 3:40-4:10pm PT and can be accessed through the Investor Relations section of Inozyme’s website under events. A replay of the event will also be available for a limited time.
Inozyme Pharma is a clinical-stage rare disease biopharmaceutical company that focuses on developing novel therapeutics for diseases affecting vasculature, soft tissue, and skeleton. The company is currently working on an enzyme replacement therapy, INZ-701, which aims to address pathologic mineralization and intimal proliferation that can lead to severe health issues. INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.
For more information about Inozyme Pharma or its products, visit their website at
